Sean Xiaochun Zhu

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 6

Top Topics

Combination Therapy

Advanced Non Small Cell Lung Cancer

Top Venues

Investigational new drugs

Drug metabolism and disposition: the biological fate of chemicals

This page only lists publications with an associated author ORCID identifier.

Publications

Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Hao Chen, Abhi Shah, Suguru Kato, Robert Griffin, Steven Zhang, Sandeepraj Pusalkar, Lawrence Cohen, Yuexian Li, Swapan K Chowdhury, Sean Xiaochun Zhu
Metabolism and excretion of [ 14 C]mobocertinib, a selective covalent inhibitor of EGFR exon 20 insertion mutants, in healthy male subjects. Drug metabolism and disposition: the biological fate of chemicals (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs 42 (4) (2024)
Michael J Hanley, Steven Zhang, Robert J Griffin, Sean Xiaochun Zhu, Robert J Fram, Jianchang Lin, Karthik Venkatakrishnan, Neeraj Gupta
A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [ 14 C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants. Investigational new drugs (2024)
Minxia Michelle He, Sean Xiaochun Zhu, Joe R Cannon, Jesper Kammersgaard Christensen, Ruchia Duggal, Mithat Gunduz, Constanze Hilgendorf, Adam Hughes, Ivy Kekessie, Maximilian Kullmann, Dennis Leung, Carsten Terjung, Kai Wang, Frank Wesche
Metabolism and excretion of therapeutic peptides: current industry practices, perspectives, and recommendations. Drug metabolism and disposition: the biological fate of chemicals (2023)